Centessa Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Centessa Pharmaceuticals has a total shareholder equity of $287.0M and total debt of $76.5M, which brings its debt-to-equity ratio to 26.7%. Its total assets and total liabilities are $398.8M and $111.9M respectively.
Key information
26.7%
Debt to equity ratio
US$76.50m
Debt
| Interest coverage ratio | n/a |
| Cash | US$294.83m |
| Equity | US$286.97m |
| Total liabilities | US$111.88m |
| Total assets | US$398.85m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 260's short term assets ($355.5M) exceed its short term liabilities ($26.8M).
Long Term Liabilities: 260's short term assets ($355.5M) exceed its long term liabilities ($85.1M).
Debt to Equity History and Analysis
Debt Level: 260 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 260's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 260 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 260 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 32.3% each year.